Cara Therapeutics, Inc. (CARA)

Cara Therapeutics, Inc. (CARA) Healthcare & Pipeline Overview

Cara Therapeutics, Inc., an early commercial-stage biopharmaceutical company, specializes in developing and commercializing therapies targeting pruritus and pain. Their lead product, KORSUVA injection, addresses moderate-to-severe pruritus associated with chronic kidney disease (CKD) in hemodialysis patients, positioning them in a niche market within the broader biotechnology sector.

What Is the Investment Thesis for CARA?

Cara Therapeutics presents a focused investment opportunity within the biotechnology sector, driven by the commercialization of KORSUVA injection for CKD-associated pruritus. The company's value hinges on the successful market penetration of KORSUVA and the expansion of its label through ongoing clinical trials of the oral formulation for various pruritic conditions. A key catalyst is the potential approval and commercial launch of Oral KORSUVA for NDD-CKD, atopic dermatitis, and other indications. However, the company's limited revenue stream, dependence on a single approved product, and the inherent risks associated with clinical trials pose significant challenges. The company's small market cap of $8.11M reflects both the potential upside and the considerable risks involved.

Based on FMP financials and quantitative analysis

CARA Key Highlights

• KORSUVA (difelikefalin) injection is the company's only commercially available product, approved for moderate-to-severe pruritus associated with chronic kidney disease (CKD) in adults undergoing hemodialysis.
• Oral KORSUVA (difelikefalin) is in Phase II clinical trials for pruritus associated with atopic dermatitis, non-dialysis-dependent chronic kidney disease (NDD-CKD), chronic liver disease (CLD) primary biliary cholangitis (PBC), and notalgia paresthetica, expanding the potential market.
• Cara has license agreements with Maruishi Pharmaceutical Co., Ltd and Chong Kun Dang Pharmaceutical Corporation for difelikefalin development and commercialization in Japan and South Korea, respectively, providing international revenue streams.
• The company's market capitalization is $0.01 billion, reflecting its early commercial stage and associated risks.
• Cara employs only 10 people, indicating a lean operational structure and reliance on strategic partnerships.

Who Are CARA's Competitors?

CARA is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are CARA's Key Strengths?

• Approved product (KORSUVA) for a specific indication (CKD-associated pruritus).
• Novel mechanism of action targeting kappa opioid receptors.
• Strategic partnerships for international expansion.
• Experienced management team focused on pruritus and pain.

What Are CARA's Weaknesses?

• Reliance on a single approved product.
• Limited revenue stream.
• Small market capitalization.
• Dependence on successful clinical trial outcomes for future growth.

What Could Drive CARA Stock Higher?

• Data readout from Phase II clinical trials of Oral KORSUVA for pruritus associated with atopic dermatitis, NDD-CKD, CLD-PBC, and notalgia paresthetica.
• Potential regulatory submissions and approvals for Oral KORSUVA in various indications.
• Continued commercialization and market penetration of KORSUVA injection for CKD-associated pruritus.
• Expansion of strategic partnerships for geographic expansion and product development.

What Are the Key Risks for CARA?

• Financial-distress signal — its Altman Z-Score of -5.37 sits in the distress zone (elevated bankruptcy risk).
• Negative return on equity (-64.2%) — the business is not currently generating profit on shareholder capital.
• Weak fundamentals — a Piotroski F-Score of 0/9 flags soft profitability, leverage or efficiency.
• Clinical trial failures for Oral KORSUVA.
• Regulatory delays or rejections.
• Competition from existing therapies and new entrants.
• Reimbursement challenges for KORSUVA.
• Dependence on a single approved product.

What Are the Growth Opportunities for CARA?

• Expansion of KORSUVA into New Indications: Oral KORSUVA is currently in Phase II clinical trials for pruritus associated with atopic dermatitis, non-dialysis-dependent chronic kidney disease (NDD-CKD), chronic liver disease (CLD) primary biliary cholangitis (PBC), and notalgia paresthetica. Successful completion of these trials and subsequent regulatory approvals could significantly expand KORSUVA's market reach, potentially addressing a multi-billion dollar market across these indications. The timeline for commercialization depends on the trial outcomes and regulatory review processes.
• Geographic Expansion through Partnerships: Cara has established partnerships with Maruishi Pharmaceutical Co., Ltd and Chong Kun Dang Pharmaceutical Corporation to develop and commercialize difelikefalin in Japan and South Korea, respectively. These partnerships provide Cara with access to new markets and revenue streams without requiring significant investment in infrastructure. Further geographic expansion through similar partnerships could drive additional growth.
• Advancement of Pipeline Programs: Cara is focused on developing product candidates that target the body's peripheral nervous system and immune cells. Continued investment in research and development could lead to the discovery and development of new therapies for pruritus and pain, diversifying the company's product portfolio and reducing its reliance on KORSUVA. The timeline for these programs is uncertain, but successful development could create significant long-term value.
• Increased Market Penetration in Hemodialysis Patients: KORSUVA injection is currently approved for the treatment of moderate-to-severe pruritus associated with chronic kidney disease (CKD) in adults undergoing hemodialysis. Increasing awareness of KORSUVA among healthcare providers and patients could drive greater market penetration and sales growth within this existing indication. This can be achieved through targeted marketing campaigns and educational initiatives.
• Potential Acquisition or Strategic Alliance: As a small-cap biotechnology company with a commercially available product, Cara could be an attractive acquisition target for a larger pharmaceutical company seeking to expand its portfolio in the pruritus and pain market. Alternatively, Cara could form a strategic alliance with another company to co-develop or co-commercialize its products, leveraging the partner's resources and expertise.

What Opportunities Does CARA Have?

• Expansion of KORSUVA into new indications (atopic dermatitis, NDD-CKD).
• Geographic expansion through partnerships.
• Advancement of pipeline programs.
• Potential acquisition or strategic alliance.

What Threats Does CARA Face?

• Competition from existing therapies and new entrants.
• Clinical trial failures.
• Regulatory hurdles.
• Reimbursement challenges.

What Are CARA's Competitive Advantages?

• Patent protection for KORSUVA (difelikefalin) provides exclusivity and limits competition.
• Established regulatory approval for KORSUVA injection creates a barrier to entry for competitors.
• Strategic partnerships with Maruishi Pharmaceutical Co., Ltd and Chong Kun Dang Pharmaceutical Corporation provide access to international markets.
• First-mover advantage in the kappa opioid receptor agonist class for pruritus treatment.

What Does CARA Do?

Cara Therapeutics, Inc. was founded in 2004 and is based in Stamford, Connecticut. The company focuses on developing and commercializing novel chemical entities with a primary focus on pruritus and pain management by selectively targeting kappa opioid receptors. Cara's approach involves developing product candidates that target the body's peripheral nervous system and immune cells, offering a unique mechanism of action compared to traditional pain and itch treatments. The company's flagship product, KORSUVA (difelikefalin) injection, is approved for the treatment of moderate-to-severe pruritus associated with chronic kidney disease (CKD) in adult hemodialysis patients. This represents Cara's first commercial product and a significant milestone for the company. In addition to the approved injectable formulation, Cara is also developing an oral formulation of KORSUVA (difelikefalin) to address pruritus in other patient populations, including those with atopic dermatitis, non-dialysis-dependent chronic kidney disease (NDD-CKD), chronic liver disease (CLD) associated with primary biliary cholangitis (PBC), and notalgia paresthetica. These oral formulations are currently in various stages of clinical development. Cara has also established strategic partnerships to expand the global reach of its products. License agreements with Maruishi Pharmaceutical Co., Ltd. and Chong Kun Dang Pharmaceutical Corporation grant these companies the rights to develop, manufacture, and commercialize difelikefalin-containing drug products in Japan and South Korea, respectively.

What Products and Services Does CARA Offer?

• Develop and commercialize therapies for pruritus and pain.
• Target kappa opioid receptors to modulate the body's response to itch and pain.
• Offer KORSUVA injection for moderate-to-severe pruritus associated with chronic kidney disease (CKD) in adults undergoing hemodialysis.
• Develop Oral KORSUVA for pruritus associated with atopic dermatitis and non-dialysis-dependent chronic kidney disease (NDD-CKD).
• Conduct clinical trials to evaluate the safety and efficacy of their product candidates.
• Establish strategic partnerships to expand the global reach of their products.

How Does CARA Make Money?

• Develop and obtain regulatory approval for pharmaceutical products.
• Commercialize approved products through direct sales and marketing efforts.
• Generate revenue through product sales and licensing agreements.
• Partner with other companies to expand market reach and share development costs.

What Industry Does CARA Operate In?

Cara Therapeutics operates in the competitive biotechnology industry, specifically targeting the pruritus and pain market. The market for pruritus treatments is driven by the high prevalence of chronic kidney disease, atopic dermatitis, and other conditions that cause persistent itching. Cara's KORSUVA competes with existing treatments like antihistamines and corticosteroids, but offers a novel mechanism of action by targeting kappa opioid receptors. The company's success depends on demonstrating the superior efficacy and safety of KORSUVA compared to these existing therapies. The biotechnology industry is characterized by high research and development costs, regulatory hurdles, and the risk of clinical trial failures.

Who Are CARA's Key Customers?

• Adults undergoing hemodialysis with moderate-to-severe pruritus associated with chronic kidney disease (CKD).
• Patients with atopic dermatitis and NDD-CKD experiencing pruritus (potential future market).
• Healthcare providers who prescribe and administer KORSUVA.
• Hospitals and dialysis centers that purchase KORSUVA.

How Cara Therapeutics, Inc. Is Valued

Cara Therapeutics, Inc. carries a market capitalization of $8.11M, placing it in the micro-cap category. Relative to its peer group, CARA's quantitative score of 50/100 is below the peer average of 79/100.

Company Profile

Cara Therapeutics, Inc. operates in the Biotechnology industry within the Healthcare sector. It is headquartered in Stamford, US. The company is led by CEO Christopher A. Posner. CARA has traded publicly since 2014.

ROE -64%Key Financial Metrics

Return on equity for Cara Therapeutics, Inc. stands at -64.2%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -59.8%, showing how much profit it generates from its asset base. A current ratio of 2.25 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is -86.6%, the inverse of the P/E and a quick read on earnings relative to price.

F-Score 0/9Financial Health

Cara Therapeutics, Inc.'s Piotroski F-Score is 0/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of -5.37 places it in the distress zone, a signal of elevated financial risk.

FY2026 estForward Outlook

Wall Street analysts project Cara Therapeutics, Inc. revenue of about $10.2M for fiscal 2026, with EPS near $-8.64.

CARA Financials

CARA Latest News

No recent news available for CARA.

CARA Analyst Consensus

CARA MoonshotScore

What Investors Ask About Cara Therapeutics, Inc. (CARA) — Healthcare

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources